IP Library Granted Patent US 10,875,936
Granted Patent B2
US 10,875,936 · App. 15/032,248 · Granted Dec 29, 2020

Derivatives of N-desulfated glycosaminoglycans and use as drugs

Inventors: Giangiacomo Torri (Milan, IT); Annamaria Naggi (Legnano, IT)
Assignee: Novahealth Biosystems, LLC
C08B37/0075A61K31/726A61K31/727A61K31/728A61K31/737C08B37/0063C08B37/0069C08B37/0072C08B37/0078
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,875,936
App. No.
15/032,248
Granted
Dec 29, 2020
Kind
B2
Abstract

The invention relates to N-desulfated and optionally 2-O-desulfated glycosaminoglycan derivatives, wherein at least part of the adjacent diols and OH/NH 2 have been converted into the corresponding aldehyde, which aldehydes have been then reduced to the corresponding alcohol. These products are endowed with heparanase inhibitory activity and anti-tumor activity. Said glycosaminoglycan derivatives are obtained from natural or synthetic glycosaminoglycan, preferably from unfractionated heparin, low molecular weight heparins (LMWHs), heparan sulfate or derivatives thereof. The invention further relates to the process for preparation of the same and further to their use as active ingredients of medicaments, also in combination with known established drugs or treatments. The present invention further relates to a process for breaking the C 2 -C 3 linkage of glucosamine residues of a glycosaminoglycan by oxidation of said glycosaminoglycan.

Claims (8)

1. A process for the preparation of a glycosaminoglycan derivative inhibiting heparanase, consisting essentially of:

a) N-desulfation of from 25% to 100% of the N-sulfated glucosamine residues of a glycosaminoglycan;

b) oxidation of from 25% to 100% of the 2-N-, 3-O-non-sulfated glucosamine residues and of the 2-O-non-sulfated uronic acid residues of said glycosaminoglycan of step a), under conditions effective to convert adjacent diols and adjacent OH/NH 2 to aldehydes;

c) reduction of said oxidized glycosaminoglycan, under conditions effective to convert said aldehydes to alcohols;

wherein the glycosaminoglycan is a natural or synthetic glycosaminoglycan, and wherein the natural or synthetic glycosaminoglycan is heparin, low-molecular-weight heparin, heparin sulfate, or fractions thereof.

2. The process of claim 1 , wherein the oxidation in step b) is by periodate at a pH of from 5.5 to 10.0.

3. The process of claim 1 , wherein the reduction in step c) is by sodium borohydride.

4. The process of claim 1 , wherein the natural or synthetic glycosaminoglycan is unfractionated heparin or heparin having a molecular weight of from 3,500 to 8,000 Da.

Assignments (4)
SECURITY INTEREST Recorded Apr 3, 2018
From: SCIENTIFIC PROTEIN LABORATORIES LLC; NOVAHEALTH BIOSYSTEMS, LLC
To: BMO HARRIS BANK N.A.
Reel/Frame 045428/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2016
From: TORRI, GIANGIACOMO; NAGGI, ANNAMARIA
To: CENTRO ALTA TECNOLOGIA ISTITUTO DI RICERCHE CHIMICHE E BIOCHIMICHE G. RONZONI S.R.L.
Reel/Frame 038960/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2016
From: CENTRO ALTA TECNOLOGIA ISTITUTO DI RICERCHE CHIMICHE E BIOCHIMICHE G. RONZONI S.R.L.
To: NOVAHEALTH BIOSYSTEMS, LLC
Reel/Frame 038961/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2016
From: TORRI, GIANGIACOMO; NAGGI, ANNAMARIA
To: CENTRO ALTA TECNOLOGIA ISTITUTO DI RICERCHE CHIMICHE E BIOCHIMICHE "G.RONZONI" S.R.
Reel/Frame 038446/0399 →
Priority Claims (1)
IT LO2013A0005 · Oct 31, 2013 · national
Continuity (1)
Related Publication 20160237178A1 · Aug 18, 2016